Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS: Algenpantucel-L in Resected Pancreatic Cancer
NCT01072981Phase 3Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Apr 2010
- Primary completion
- May 2016
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of algenpantucel-L in pancreatic cancer (PC), sponsored by Lumos Pharma, Inc.. Started Apr 2010; status: completed.
02
Drugs
algenpantucel-L
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01072981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01072981.